Literature DB >> 24865441

Psychological morbidity associated with ovarian cancer screening: results from more than 23,000 women in the randomised trial of ovarian cancer screening (UKCTOCS).

J Barrett1, V Jenkins, V Farewell, U Menon, I Jacobs, J Kilkerr, A Ryan, C Langridge, L Fallowfield.   

Abstract

OBJECTIVE: To examine the psychological sequelae associated with abnormal screening in the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
DESIGN: Prospective, longitudinal randomised control trial.
SETTING: Sixteen UKCTOCS centres. SAMPLE: Women aged 50-70 years randomised to annual multimodal screening, ultrasound screening or control groups.
METHODS: Two groups were followed for 7 years: (1) a random sample (n = 1339), taken from all three study groups; and (2) an events sample (n = 22,035) of women with abnormal screens resulting in the need for repeat testing of either low or higher level intensity. MAIN OUTCOME MEASURES: Patient-reported measures of anxiety (scores ranging from 20 to 80) and psychological morbidity.
RESULTS: In the random sample the mean difference between anxiety scores after a repeat screening and those following an annual screening was 0.4 (95% CI -0.46, 1.27), and in the events sample it was 0.37 (95% CI 0.23, 0.51). The risk of psychological morbidity was only increased in the event sample for women requiring higher level repeat screening (OR 1.28; 95% CI 1.18, 1.39). The risk of psychological morbidity in women with ovarian cancer was higher at both 6 weeks (OR 16.2; 95% CI 9.19, 28.54) and 6 months (OR 3.32; 95% CI 1.91, 5.77) following surgery.
CONCLUSIONS: Screening does not appear to raise anxiety but psychological morbidity is elevated by more intense repeat testing following abnormal annual screens, and in women after surgical treatment for ovarian cancer.
© 2014 Royal College of Obstetricians and Gynaecologists.

Entities:  

Keywords:  Anxiety; ovarian cancer; population screening programme; psychological morbidity

Mesh:

Year:  2014        PMID: 24865441     DOI: 10.1111/1471-0528.12870

Source DB:  PubMed          Journal:  BJOG        ISSN: 1470-0328            Impact factor:   6.531


  18 in total

1.  Factors associated with deciding between risk-reducing salpingo-oophorectomy and ovarian cancer screening among high-risk women enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group study.

Authors:  Phuong L Mai; Marion Piedmonte; Paul K Han; Richard P Moser; Joan L Walker; Gustavo Rodriguez; John Boggess; Thomas J Rutherford; Oliver Zivanovic; David E Cohn; J Tate Thigpen; Robert M Wenham; Michael L Friedlander; Chad A Hamilton; Jamie Bakkum-Gamez; Alexander B Olawaiye; Martee L Hensley; Mark H Greene; Helen Q Huang; Lari Wenzel
Journal:  Gynecol Oncol       Date:  2017-02-10       Impact factor: 5.482

Review 2.  Gynecological Cancers-the Changing Paradigm.

Authors:  P Rema
Journal:  Indian J Surg Oncol       Date:  2018-11-29

3.  Demographic, clinical, dispositional, and social-environmental characteristics associated with psychological response to a false positive ovarian cancer screening test: a longitudinal study.

Authors:  Amanda T Wiggins; Edward J Pavlik; Michael A Andrykowski
Journal:  J Behav Med       Date:  2017-10-25

Review 4.  Novel Approaches to Ovarian Cancer Screening.

Authors:  Denise R Nebgen; Karen H Lu; Robert C Bast
Journal:  Curr Oncol Rep       Date:  2019-07-26       Impact factor: 5.075

Review 5.  Current and Emerging Methods for Ovarian Cancer Screening and Diagnostics: A Comprehensive Review.

Authors:  Juliane M Liberto; Sheng-Yin Chen; Ie-Ming Shih; Tza-Huei Wang; Tian-Li Wang; Thomas R Pisanic
Journal:  Cancers (Basel)       Date:  2022-06-11       Impact factor: 6.575

6.  Affective, cognitive and behavioral outcomes associated with a false positive ovarian cancer screening test result.

Authors:  Amanda T Wiggins; Edward J Pavlik; Michael A Andrykowski
Journal:  J Behav Med       Date:  2017-04-21

7.  Prospective follow-up of quality of life for participants undergoing risk-reducing salpingo-oophorectomy or ovarian cancer screening in GOG-0199: An NRG Oncology/GOG study.

Authors:  Phuong L Mai; Helen Q Huang; Lari B Wenzel; Paul K Han; Richard P Moser; Gustavo C Rodriguez; John Boggess; Thomas J Rutherford; David E Cohn; Noah D Kauff; Kelly-Anne Phillips; Kelly Wilkinson; Robert M Wenham; Chad Hamilton; Matthew A Powell; Joan L Walker; Mark H Greene; Martee L Hensley
Journal:  Gynecol Oncol       Date:  2019-11-21       Impact factor: 5.482

Review 8.  Major clinical research advances in gynecologic cancer in 2015.

Authors:  Dong Hoon Suh; Miseon Kim; Hak Jae Kim; Kyung Hun Lee; Jae Weon Kim
Journal:  J Gynecol Oncol       Date:  2016-11       Impact factor: 4.401

9.  Psychosocial Factors Associated With Withdrawal From the United Kingdom Collaborative Trial of Ovarian Cancer Screening After 1 Episode of Repeat Screening.

Authors:  Valerie Jenkins; Lesley Fallowfield; Carolyn Langridge; Jessica Barrett; Andy Ryan; Ian Jacobs; Justine Kilkerr; Usha Menon; Vernon Farewell
Journal:  Int J Gynecol Cancer       Date:  2015-10       Impact factor: 3.437

10.  Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial.

Authors:  Ian J Jacobs; Usha Menon; Andy Ryan; Aleksandra Gentry-Maharaj; Matthew Burnell; Jatinderpal K Kalsi; Nazar N Amso; Sophia Apostolidou; Elizabeth Benjamin; Derek Cruickshank; Danielle N Crump; Susan K Davies; Anne Dawnay; Stephen Dobbs; Gwendolen Fletcher; Jeremy Ford; Keith Godfrey; Richard Gunu; Mariam Habib; Rachel Hallett; Jonathan Herod; Howard Jenkins; Chloe Karpinskyj; Simon Leeson; Sara J Lewis; William R Liston; Alberto Lopes; Tim Mould; John Murdoch; David Oram; Dustin J Rabideau; Karina Reynolds; Ian Scott; Mourad W Seif; Aarti Sharma; Naveena Singh; Julie Taylor; Fiona Warburton; Martin Widschwendter; Karin Williamson; Robert Woolas; Lesley Fallowfield; Alistair J McGuire; Stuart Campbell; Mahesh Parmar; Steven J Skates
Journal:  Lancet       Date:  2015-12-17       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.